The invention concerns quinazoline derivatives of the Formula I, or pharmaceutically acceptable salts thereof:
wherein each of R1, R2, R3, R4 and m are as defined in the description; processes for their preparation; pharmaceutical compositions containing them and their use in the manufacture of a medicament for providing an anti-proliferative effect. The quinazoline derivatives of Formula I are expected to be useful in the treatment of diseases such as certain cancers mediated by erbB receptor tyrosine kinases, and, for example, EGFR tyrosine kinase.
本发明涉及式I的喹嗪衍
生物,或其药学上可接受的盐:其中R1、R2、R3、R4和m的定义如描述中所定义;它们的制备方法;含有它们的制药组合物以及它们在制造提供抗增殖效应的药物方面的应用。预计式I的喹嗪衍
生物可用于治疗某些经由erbB受体
酪氨酸激酶介导的癌症,例如
EGFR
酪氨酸激酶。